Gain Therapeutics, Inc.
GANXGain Therapeutics, Inc. in brief
Gain Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Bethesda, Maryland, USA. It was founded in 2017. Its market value was $74 M on 7 October 2026, which makes it the 19,829th largest listed company in the world and the 3,679th largest in the USA on this site. It employs about 20 people and Gene Mack is its chief executive. Its shares trade under the symbol GANX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Gain Therapeutics, Inc.
We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people with Parkinson’s disease with or without a GBA1 mutation.
We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287. In preclinical models of GBA1 and idiopathic Parkinson’s disease, GT-02287 has been shown to restore glucocerebrosidase, or GCase, function in the lysosome, improve mitochondrial health, reduce toxic lipid substrates and toxic forms of alpha-synuclein, reduce neuroinflammation, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function and improve cognition, and reduce plasma-based neurodegeneration maker, neurofilament light chain (NfL) back to the level of healthy animals.
From the company's annual report filed with the US SEC: read the report
Gain Therapeutics, Inc. timeline
- 2017
- 🏁· approximateFounded
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 22 March 2021; shares registered for exchange trading on 17 March 2021.
Events of Gain Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,763 (Jan 2022) · #4,975 (Dec 2022) · #4,763 (Jul 2023) · #3,982 (Jan 2024) · #1,810 (Mar 2026) · #3,460 (Aug 2026) · #3,657 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 4.0×
- Free cash flow yield
- -25.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -108.6%
- Liabilities / assets
- 18.6%
- Net debt
- $-20M
- Revenue growth
- -57.1%
- R&D / revenue
- 19200.0%
- Profit per employee
- $-1.0 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-19M | $-20M | — |
| Dec 2024 | — | — | $-20M | $-20M | — |
| Dec 2023 | $0M | -57.1% | $-22M | $-22M | -37116.7% |
| Dec 2022 | $0M | -12.5% | $-18M | $-18M | -12564.3% |
| Dec 2021 | $0M | — | $-14M | $-14M | -8681.3% |
| Dec 2020 | — | — | $-3M | $-4M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-18M | — | — | $-0.61 | — |
| Dec 2024 | $-19M | $0M | $-19M | $-0.89 | — |
| Dec 2023 | $-19M | $0M | $-19M | $-1.71 | — |
| Dec 2022 | $-15M | $0M | $-15M | $-1.48 | — |
| Dec 2021 | $-12M | $0M | $-12M | $-1.37 | — |
| Dec 2020 | $-3M | $0M | $-3M | $-1.33 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 28, 20268-KCurrent reportDirectors or officers changed
- Oct 1, 20268-KCurrent reportOther events
- Sep 28, 20268-KCurrent reportDirectors or officers changed
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 16, 20268-KCurrent reportOther events
- Jun 29, 20268-KCurrent reportOther events
- Jun 25, 20268-KCurrent reportShareholder vote
- May 26, 20268-KCurrent reportOther events
- May 11, 202610-QQuarterly report · period to Mar 2026
Official filings of Gain Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-19 M
- Net income
- $-20 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $23 M
- Total liabilities
- $4 M
- Total equity
- $19 M
As of December-2025
Top 50 institutional investors in Gain Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Marshall Wace, LLP | 1,680,811 | -242,735 (-12.62%) | 3.77% | $3 M | Nov 13, 2026 |
| 2 | Potomac Capital Management, Inc. | 930,000 | -16,400 (-1.73%) | 2.09% | $2 M | Nov 13, 2026 |
| 3 | Jones Financial Companies Lllp | 739,432 | +130,840 (+21.50%) | 1.66% | $1 M | Nov 13, 2026 |
| 4 | Gsa Capital Partners LLP | 634,716 | +2,585 (+0.41%) | 1.43% | $1 M | Nov 16, 2026 |
| 5 | Cambridge Investment Research Advisors, Inc. | 566,645 | -570,645 (-50.18%) | 1.27% | $1 M | Nov 2, 2026 |
| 6 | DME Capital Management, LP | 566,130 | 0 (0.00%) | 1.27% | $1 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 480,269 | 0 (0.00%) | 1.08% | $1 M | Nov 13, 2026 |
| 8 | Geode Capital Management, LLC | 469,535 | +16,034 (+3.54%) | 1.05% | $1 M | Nov 6, 2026 |
| 9 | BlackRock, Inc. | 268,321 | -6,636 (-2.41%) | 0.60% | $0 M | Nov 13, 2026 |
| 10 | UBS Group AG | 241,483 | +26,471 (+12.31%) | 0.54% | $0 M | Nov 10, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 231,534 | 0 (0.00%) | 0.52% | $0 M | Nov 13, 2026 |
| 12 | Cresset Asset Management, LLC | 220,000 | +60,000 (+37.50%) | 0.49% | $0 M | Nov 16, 2026 |
| 13 | State Street Corp | 199,537 | +42,000 (+26.66%) | 0.45% | $0 M | Nov 12, 2026 |
| 14 | Renaissance Technologies LLC | 182,600 | New | 0.41% | $0 M | Nov 12, 2026 |
| 15 | Citadel Advisors LLC | 170,230 | +15,706 (+10.16%) | 0.38% | $0 M | Nov 16, 2026 |
| 16 | LPL Financial LLC | 117,251 | 0 (0.00%) | 0.26% | $0 M | Nov 6, 2026 |
| 17 | Morgan Stanley | 105,772 | -20,200 (-16.04%) | 0.24% | $0 M | Nov 13, 2026 |
| 18 | Northern Trust Corp | 97,013 | 0 (0.00%) | 0.22% | $0 M | Nov 16, 2026 |
| 19 | Commonwealth Equity Services, LLC | 57,881 | -575 (-0.98%) | 0.13% | $0 M | Nov 2, 2026 |
| 20 | Bridgeway Capital Management, LLC | 52,238 | +22,234 (+74.10%) | 0.12% | $0 M | Nov 16, 2026 |
| 21 | Empowered Funds, LLC | 52,238 | New | 0.12% | $0 M | Nov 13, 2026 |
| 22 | Prelude Capital Management, LLC | 35,820 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 23 | Apollon Wealth Management, LLC | 31,500 | +5,000 (+18.87%) | 0.07% | $0 M | Oct 23, 2026 |
| 24 | Simplex Trading, LLC | 28,457 | New | 0.06% | $0 M | Nov 4, 2026 |
| 25 | StoneX Group Inc. | 25,118 | New | 0.06% | $0 M | Nov 3, 2026 |
Show all 50: investors 26 to 50
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Oliver Luxxe Assets LLC | 20,250 | 0 (0.00%) | 0.05% | $0 M | Oct 14, 2026 |
| 27 | Bokf, NA | 20,000 | New | 0.04% | $0 M | Oct 27, 2026 |
| 28 | Vanguard Global Advisers, LLC | 18,376 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 29 | HighTower Advisors, LLC | 17,174 | 0 (0.00%) | 0.04% | $0 M | Nov 10, 2026 |
| 30 | Wealth Enhancement Advisory Services, LLC | 17,056 | 0 (0.00%) | 0.04% | $0 M | Oct 13, 2026 |
| 31 | Wealthspire Advisors, LLC | 16,900 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 32 | Jpmorgan Chase & Co | 15,960 | +14,260 (+838.82%) | 0.04% | $0 M | Nov 12, 2026 |
| 33 | Sandhill Capital Partners LLC | 15,400 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 34 | Crux Wealth Advisors | 14,925 | New | 0.03% | $0 M | Nov 10, 2026 |
| 35 | HRT Financial LP | 14,903 | New | 0.03% | $0 M | Nov 13, 2026 |
| 36 | Benedict Financial Advisors Inc | 13,500 | -21,500 (-61.43%) | 0.03% | $0 M | Oct 7, 2026 |
| 37 | HB Wealth Management, LLC | 12,783 | 0 (0.00%) | 0.03% | $0 M | Oct 23, 2026 |
| 38 | R Squared Ltd | 11,584 | New | 0.03% | $0 M | Nov 6, 2026 |
| 39 | Harbour Investments, Inc. | 10,745 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 40 | NewEdge Advisors, LLC | 10,600 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 41 | Mercer Global Advisors Inc /adv | 10,000 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 42 | Sanctuary Advisors, LLC | 10,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 43 | Tower Research Capital LLC (TRC) | 4,728 | -3,593 (-43.18%) | 0.01% | $0 M | Nov 16, 2026 |
| 44 | Royal Bank Of Canada | 2,278 | New | 0.01% | $0 M | Nov 16, 2026 |
| 45 | Arax Advisory Partners | 1,700 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 46 | Wells Fargo & Company/mn | 1,000 | -8,400 (-89.36%) | 0.00% | $0 M | Nov 16, 2026 |
| 47 | Pinnacle Financial Group, Inc. | 600 | — | 0.00% | $0 M | Nov 16, 2026 |
| 48 | Caitong International Asset Management Co., Ltd | 101 | -64 (-38.79%) | 0.00% | $0 M | Oct 29, 2026 |
| 49 | Larson Financial Group LLC | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 50 | Barclays PLC | 2 | -1,350 (-99.85%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Gain Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 430,902 | $1 M | 0.97% | <0.01% | +7.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 207,106 | $0 M | 0.47% | <0.01% | +6.7% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 144,159 | $0 M | 0.32% | 0.02% | +51% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 57,335 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 55,636 | $0 M | 0.12% | <0.01% | +6.5% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 30,004 | $0 M | 0.07% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 28,629 | $0 M | 0.06% | <0.01% | +185% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,730 | $0 M | 0.02% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 966 | $0 M | <0.01% | <0.01% | +32% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Gain Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Khalid IslamExecutive Chairman, Director | Buy | +50,000 | $1.000 | $50 K | 50,000 | Form 4 |
| filed | Gene MackCFO and Interim CEO | Buy | +14,400 | $1.010 | $15 K | 14,400 | Form 4 |
| filed | Eric I. RichmanDirector | Buy | +5,000 | $1.230 | $6 K | 277,629 | Form 4 |
| filed | Eric I. RichmanDirector | Buy | +12,000 | $1.210 | $15 K | 289,629 | Form 4 |
| filed | Jeffrey Scott RileyDirector | Buy | +30,000 | $3.860 | $116 K | 30,000 | Form 4 |
| filed | Matthias AlderChief Executive Officer, Director | Option exercise | +18,750 | — | — | 25,763 | Form 4 |
| filed | Matthias AlderChief Executive Officer, Director | Option exercise | +825 | — | — | 26,588 | Form 4 |
| filed | Matthias AlderChief Executive Officer, Director | Option exercise | +637 | — | — | 27,225 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Gain Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1 split ; 10-for-1 split
Trading halts
- 2025-12-18 15:03 UTC, code LUDP, resumed 15:13 UTC
- 2025-12-18 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2025-12-18 14:41 UTC, code LUDP, resumed 14:56 UTC
- 2025-12-18 14:30 UTC, code LUDP, resumed 14:40 UTC
Fails to deliver
- : 5,043 shares at $1.67
- : 4,565 shares at $1.75
- : 399 shares at $2.01
- : 1,424 shares at $2.12
- : 4,211 shares at $2.17
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Gain Therapeutics, Inc. scorecard#
Passes 3 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 7, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.0×Price to book 4.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-25.4%Free cash flow is -25.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.61 vs -0.89Diluted EPS -0.61 in fiscal 2025 against -0.89 the year before (report's currency).
- ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$4 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-155.7%-155.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 4
- ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.64 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.02 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $20 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year44.1%Diluted shares up 44.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Gain Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | 0.1−60.6%100% | 0.1−15.1%100% | 0.2+471%100% | 0.0—100% | |
| Research and development | 10−5.4%— | 11−6.3%— | 12+37.5%20878% | 8.4+16.9%5979% | 7.2+217%4342% | 2.3—7822% | |
| General and administrative | 8.5−11.1%— | 9.6−11.4%— | 11+13.1%19550% | 9.5+39.7%6809% | 6.8+447%4138% | 1.2—4325% | |
| Operating expenses | 19−8.1%— | 20−8.8%— | 22+24.5%40428% | 18+28.1%12788% | 14+299%8480% | 3.5—12148% | |
| Operating income | −19—— | −20—— | −22—−40328% | −18—−12688% | −14—−8380% | −3.5—−12048% | |
| Interest expense and finance costs | — | — | — | — | 0—0.0% | — | |
| Net interest income | — | — | 0.5+31.7%896% | 0.4+2904%268% | 0.0+244%7.6% | 0.0—12.6% | |
| Income before tax | −19—— | −20—— | −22—−40211% | −17—−12489% | −14—−8416% | −3.6—−12369% | |
| Income tax | 0.9+60.4%— | 0.5+577%— | 0.1−14.7%144% | 0.1+2220%66.4% | 0.0−25.6%2.4% | 0.0—18.6% | |
| Net income including minority interests | −20—— | −20—— | −22—−40354% | −18—−12555% | −14—−8419% | −3.6—−12388% | |
| Net income attributable to shareholders | −20—— | −20—— | −22—−40354% | −18—−12555% | −14—−8419% | −3.6—−12388% | |
| Earnings per share, basic | -0.61—— | -0.89—— | -1.71—— | -1.48—— | -1.37—— | -1.33—— | |
| Earnings per share, diluted | -0.61—— | -0.89—— | -1.71—— | -1.48—— | -1.37—— | -1.33—— | |
| Shares, weighted average (basic) | 33+44.1%— | 23+75.9%— | 13+9.5%— | 12+16.9%— | 10+279%— | 2.7—— | |
| Shares, weighted average (diluted) | 33+44.1%— | 23+75.9%— | 13+9.5%— | 12+16.9%— | 10+279%— | 2.7—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 21+101%91.3% | 10−11.9%85.7% | 12+61.3%63.4% | 7.3−80.2%30.3% | 37+392%94.6% | 7.5—78.0% | |
| Short-term investments | — | — | 5.0−61.0%26.9% | 13—53.2% | — | — | |
| Receivables | — | — | — | — | — | 0.0—0.1% | |
| Other current assets | 1.2+29.0%5.3% | 0.9+27.5%7.8% | 0.7−12.6%4.0% | 0.8+16.6%3.5% | 0.7+266%1.9% | 0.2r0.3—2.1% | |
| Current assets | 22+91.7%97.5% | 12−34.7%95.7% | 18−15.7%95.5% | 21−44.1%87.5% | 38+320%96.8% | 9.0—93.6% | |
| Property, plant and equipment | 0.1−27.7%0.3% | 0.1−17.7%0.9% | 0.1−12.8%0.7% | 0.1+36.2%0.6% | 0.1+258%0.3% | 0.0—0.3% | |
| Right-of-use (leased) assets | 0.3+52.1%1.5% | 0.2−52.2%1.8% | 0.5−30.4%2.5% | 0.7−26.8%2.7% | 0.9+72.3%2.3% | 0.5—5.4% | |
| Other intangible assets | 0.1—0.5% | — | — | — | — | — | |
| Non-current assets | 0.6+11.6%2.5% | 0.5−37.2%4.3% | 0.8−72.4%4.5% | 3.0+138%12.5% | 1.3+105%3.2% | 0.6—6.4% | |
| Total assets | 23+88.2%100% | 12−34.9%100% | 19−22.8%100% | 24−38.2%100% | 39+306%100% | 9.6—100% | |
| Accounts payable | 0.8−12.8%3.6% | 0.9−28.3%7.8% | 1.3−18.9%7.1% | 1.6+190%6.7% | 0.6−41.7%1.4% | 1.0—10.0% | |
| Debt due within a year | 0.1−8.4%0.4% | 0.1−7.3%0.9% | 0.1+9.9%0.6% | 0.1+4.2%0.4% | 0.1+359%0.3% | 0.0—0.2% | |
| Current liabilities | 3.4−14.3%14.7% | 3.9−21.0%32.3% | 4.9+20.0%26.6% | 4.1+61.6%17.1% | 2.6+20.7%6.5% | 2.1—22.0% | |
| Long-term debt | 0.3−8.6%1.3% | 0.3−26.9%2.7% | 0.4−9.3%2.4% | 0.5−16.1%2.1% | 0.6−17.5%1.5% | 0.7—7.5% | |
| Lease liabilities (non-current) | 0.2+294%0.9% | 0.1−76.7%0.4% | 0.2−48.0%1.2% | 0.4−36.4%1.8% | 0.7+73.6%1.8% | 0.4—4.2% | |
| Non-current liabilities | 0.9+3.3%4.0% | 0.9−19.3%7.2% | 1.1−1.2%5.8% | 1.1−32.2%4.5% | 1.6+25.4%4.1% | 1.3—13.4% | |
| Total liabilities | 4.3−11.1%18.6% | 4.8−20.7%39.5% | 6.0+15.5%32.4% | 5.2+25.3%21.7% | 4.2+22.5%10.7% | 3.4—35.4% | |
| Retained earnings | −101r−81—−444% | −61—−501% | −39—−207% | −21—−86.8% | −7.0—−18.0% | −3.5—−36.0% | |
| Shareholders' equity | 19+153%81.4% | 7.3−41.6%60.5% | 13−33.4%67.6% | 19−45.8%78.3% | 35+461%89.3% | 6.2—64.6% | |
| Total liabilities and equity | 23+88.2%100% | 12−34.9%100% | 19−22.8%100% | 24−38.2%100% | 39+306%100% | 9.6—100% | |
| Shares outstanding | 42+55.1%— | 27+67.4%— | 16+36.4%— | 120.0%— | 12+235%— | 3.5r7.7—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.1+11.9%— | 0.1+0.6%— | 0.1+30.3%151% | 0.1+314%45.8% | 0.0+61.4%9.4% | 0.0—33.2% | |
| Share-based compensation | 1.8−24.6%— | 2.4−26.7%— | 3.3+114%5906% | 1.5+81.9%1089% | 0.8+928%509% | 0.1—283% | |
| Cash from operating activities | −18—— | −19—— | −19—−34190% | −15—−10486% | −12—−7495% | −3.2—−11219% | |
| Capital expenditure | — | −0.0—— | −0.0—−27.8% | −0.1—−84.9% | −0.1—−57.1% | −0.0—−72.1% | |
| Cash from investing activities | — | 5.0−51.3%— | 10—18526% | −15—−10545% | −0.1—−57.1% | −0.0—−72.1% | |
| Debt issued | — | — | — | — | — | 0.7—2556% | |
| Cash from financing activities | 28+119%— | 13+2.9%— | 13—22909% | −0.1−100%−56.2% | 42+298%25314% | 10—36311% | |
| Exchange-rate effect on cash | 0.5—— | −0.5−208%— | 0.5—885% | −0.0−124%−17.0% | 0.1—61.1% | −0.0—−122% | |
| Change in cash | 10—— | −1.4−131%— | 4.5—8131% | −30−201%−21105% | 29+309%17823% | 7.2—24897% | |
| Report | 10-Q | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Research and development | 8.7−4.6%— | 1.4−50.1%— | 2.1−22.5%— | 2.8+22.4%— | 2.3*+91.6%— | 2.8+8.7%— | 2.8−37.8%— | 2.3−10.0%— | 1.2*−48.4%— | 2.6—— | 4.4—— | 2.5—— | 2.4*—— | |
| General and administrative | 9.0+6.5%— | 1.8−8.0%— | 2.5+9.1%— | 2.6+22.6%— | 2.1*+0.6%— | 1.9+5.4%— | 2.3−37.8%— | 2.1+12.9%— | 2.1*+3.6%— | 1.8—— | 3.7—— | 1.9—— | 2.0*—— | |
| Operating expenses | 18+0.7%— | 3.2−33.1%— | 4.7−8.0%— | 5.4+22.5%— | 4.5*+34.1%— | 4.8+7.3%— | 5.1−37.8%— | 4.4−0.2%— | 3.3*−24.4%— | 4.5—— | 8.2—— | 4.4—— | 4.4*—— | |
| Operating income | −18—— | −3.2—— | −4.7—— | −5.4—— | −4.5*—— | −4.8—— | −5.1—— | −4.4—— | −3.3*—— | −4.5—— | −8.2—— | −4.4—— | −4.4*—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | 0.1—— | 0.1—— | 0.1—— | 0.1*—— | |
| Income before tax | −18—— | −3.1—— | −4.6—— | −5.4—— | −4.5*—— | −4.7—— | −5.7—— | −4.4—— | −3.3*—— | −4.5—— | −8.1—— | −4.0—— | −4.7*—— | |
| Income tax | 0.4−66.8%— | 0.1−86.8%— | 0.1−26.3%— | 0.2+82.1%— | 0.1*−86.1%— | 0.5+4896%— | 0.1+11579%— | 0.1+406%— | 0.5*+3380%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Net income including minority interests | −18—— | −3.2*—— | −4.7*—— | −5.6—— | −4.5*—— | −5.3*—— | −5.8*—— | −4.5—— | −3.8*—— | −4.5*—— | −8.1*—— | −4.0—— | −4.7*—— | |
| Net income attributable to shareholders | −18—— | −3.2—— | −4.7—— | −5.6—— | −4.5*—— | −5.3—— | −5.8—— | −4.5—— | −3.8*—— | −4.5—— | −8.1—— | −4.0—— | −4.7*—— | |
| Earnings per share, basic | — | -0.07—— | -0.11—— | -0.13—— | — | -0.15—— | -0.19—— | -0.16—— | — | -0.17—— | -0.42—— | -0.22—— | — | |
| Earnings per share, diluted | — | -0.07—— | -0.11—— | -0.13—— | — | -0.15—— | -0.19—— | -0.16—— | — | -0.17—— | -0.42—— | -0.22—— | — | |
| Shares, weighted average (basic) | 44+25.1%— | 44+25.1%— | 43+41.3%— | 42+47.2%— | — | 35+31.9%— | 30+57.9%— | 29+59.6%— | — | 27—— | 19—— | 18—— | — | |
| Shares, weighted average (diluted) | 44+25.1%— | 44+25.1%— | 43+41.3%— | 42+47.2%— | — | 35+31.9%— | 30+57.9%— | 29+59.6%— | — | 27—— | 19—— | 18—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 12—88.4% | 12+32.8%88.4% | 13+95.5%84.8% | 17+82.3%88.3% | 21+101%91.3% | 8.8−26.9%80.3% | 6.7−60.5%68.1% | 9.1−14.8%78.0% | 10−11.9%85.7% | 12—83.9% | 17—88.2% | 11—73.0% | 12—63.4% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | 2.0—13.9% | 5.0—26.9% | |
| Other current assets | 0.9—6.9% | 0.9−36.1%6.9% | 1.7−27.0%10.9% | 1.5−20.8%7.7% | 1.2+29.0%5.3% | 1.4+9.1%13.1% | 2.3+78.0%23.3% | 1.8+92.4%15.8% | 0.9+27.5%7.8% | 1.3—9.2% | 1.3—6.7% | 1.0—6.5% | 0.7—4.0% | |
| Current assets | 13—96.0% | 13+20.7%96.0% | 15+60.8%97.1% | 18+63.4%97.2% | 22+91.7%97.5% | 11−23.5%95.9% | 9.3−49.8%94.6% | 11−19.6%95.9% | 12−34.7%95.7% | 14—95.7% | 19—96.6% | 14—95.1% | 18—95.5% | |
| Property, plant and equipment | 0.0—0.3% | 0.0−52.9%0.3% | 0.0−51.1%0.3% | 0.1−44.2%0.3% | 0.1−27.7%0.3% | 0.1−28.5%0.8% | 0.1−22.4%1.0% | 0.1−12.9%0.8% | 0.1−17.7%0.9% | 0.1—0.8% | 0.1—0.6% | 0.1—0.8% | 0.1—0.7% | |
| Right-of-use (leased) assets | 0.4—2.8% | 0.4+99.3%2.8% | 0.3+14.4%1.7% | 0.3+63.7%1.6% | 0.3+52.1%1.5% | 0.2−34.5%1.7% | 0.2−28.4%2.4% | 0.2−52.2%1.6% | 0.2−52.2%1.8% | 0.3—2.0% | 0.3—1.7% | 0.4—2.6% | 0.5—2.5% | |
| Other intangible assets | 0.1—0.5% | 0.1—0.5% | — | — | 0.1—0.5% | — | — | — | — | — | — | — | — | |
| Non-current assets | 0.5—4.0% | 0.5+17.5%4.0% | 0.5−14.2%2.9% | 0.5+9.3%2.8% | 0.6+11.6%2.5% | 0.5−27.2%4.1% | 0.5−19.8%5.4% | 0.5−33.9%4.1% | 0.5−37.2%4.3% | 0.6—4.3% | 0.7—3.4% | 0.7—4.9% | 0.8—4.5% | |
| Total assets | 13—100% | 13+20.6%100% | 15+56.8%100% | 19+61.2%100% | 23+88.2%100% | 11−23.6%100% | 9.8−48.8%100% | 12−20.3%100% | 12−34.9%100% | 14—100% | 19—100% | 15—100% | 19—100% | |
| Accounts payable | 0.6—4.6% | 0.6−61.8%4.6% | 1.2−55.0%7.9% | 1.5−29.5%8.1% | 0.8−12.8%3.6% | 1.6+43.6%14.4% | 2.7+32.5%27.6% | 2.2+53.1%18.5% | 0.9−28.3%7.8% | 1.1—7.6% | 2.0—10.7% | 1.4—9.6% | 1.3—7.1% | |
| Debt due within a year | 0.1—0.9% | 0.1−4.7%0.9% | 0.1−2.0%0.8% | 0.1−11.4%0.5% | 0.1−8.4%0.4% | 0.1+6.1%1.1% | 0.1+13.6%1.3% | 0.1+2.1%1.0% | 0.1−7.3%0.9% | 0.1—0.8% | 0.1—0.6% | 0.1—0.8% | 0.1—0.6% | |
| Current liabilities | 2.4—17.9% | 2.4−43.2%17.9% | 3.4−33.9%22.3% | 3.9−22.7%20.7% | 3.4−14.3%14.7% | 4.2−9.2%38.0% | 5.2−20.3%52.8% | 5.0+0.5%43.3% | 3.9−21.0%32.3% | 4.6—32.0% | 6.5—34.0% | 5.0—34.3% | 4.9—26.6% | |
| Long-term debt | 0.2—1.4% | 0.2−36.7%1.4% | 0.2−32.4%1.4% | 0.3−13.1%1.5% | 0.3−8.6%1.3% | 0.3−20.6%2.7% | 0.3−13.3%3.3% | 0.3−20.8%2.7% | 0.3−26.9%2.7% | 0.4—2.6% | 0.4—2.0% | 0.4—2.7% | 0.4—2.4% | |
| Lease liabilities (non-current) | 0.2—1.6% | 0.2+231%1.6% | 0.2+68.8%1.0% | 0.2+495%1.0% | 0.2+294%0.9% | 0.1−32.4%0.6% | 0.1−30.9%0.9% | 0.0−82.8%0.3% | 0.1−76.7%0.4% | 0.1—0.7% | 0.1—0.7% | 0.2—1.2% | 0.2—1.2% | |
| Non-current liabilities | 0.7—5.4% | 0.7−20.1%5.4% | 0.7−26.0%4.5% | 0.8+3.6%4.5% | 0.9+3.3%4.0% | 0.9+3.5%8.1% | 0.9+5.9%9.6% | 0.8−12.4%7.0% | 0.9−19.3%7.2% | 0.9—6.0% | 0.9—4.6% | 0.9—6.4% | 1.1—5.8% | |
| Total liabilities | 3.1—23.3% | 3.1−39.1%23.3% | 4.1−32.7%26.8% | 4.7−19.0%25.3% | 4.3−11.1%18.6% | 5.1−7.2%46.1% | 6.1−17.2%62.4% | 5.8−1.5%50.3% | 4.8−20.7%39.5% | 5.5—38.0% | 7.4—38.6% | 5.9—40.7% | 6.0—32.4% | |
| Retained earnings | −115—−868% | −115—−868% | −112—−724% | −101—−541% | −101r−81—−444% | −81—−740% | −81—−826% | −81—−699% | −61—−501% | −61—−423% | −61—−317% | −61—−417% | −39—−207% | |
| Shareholders' equity | 10—76.7% | 10+71.8%76.7% | 11+206%73.2% | 14+142%74.7% | 19+153%81.4% | 5.9−33.7%53.9% | 3.7−68.6%37.6% | 5.8−33.1%49.7% | 7.3−41.6%60.5% | 8.9—62.0% | 12—61.4% | 8.6—59.3% | 13—67.6% | |
| Total liabilities and equity | 13—100% | 13+20.6%100% | 15+56.8%100% | 19+61.2%100% | 23+88.2%100% | 11−23.6%100% | 9.8−48.8%100% | 12−20.3%100% | 12−34.9%100% | 14—100% | 19—100% | 15—100% | 19—100% | |
| Shares outstanding | 44—— | 44+23.2%— | 43+40.8%— | 42+47.8%— | 42+55.1%— | 36+38.6%— | 31+22.2%— | 29+59.3%— | 27+67.4%— | 26—— | 25—— | 18—— | 16—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+10.2%— | 0.0*−15.6%— | 0.0*+21.7%— | 0.0+3.1%— | 0.0*+32.5%— | 0.0*+5.4%— | 0.0*+8.4%— | 0.0+0.6%— | 0.0*−9.7%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 1.7−0.8%— | 0.4−18.3%— | 0.6+8.4%— | 0.4−3.8%— | 0.4*+11.8%— | 0.5+28.7%— | 0.5−64.8%— | 0.4+120%— | 0.4*−35.3%— | 0.4—— | 1.5—— | 0.2—— | 0.6*—— | |
| Cash from operating activities | −17—— | −3.0*—— | −4.7*—— | −4.7—— | −4.6*—— | −4.9*—— | −5.1*—— | −3.8—— | −3.5*—— | −6.1*—— | −5.8*—— | −3.6—— | −5.7*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | −0.0*—— | −0.0*—— | — | — | −0.0*—— | |
| Cash from investing activities | — | — | — | — | — | — | — | — | −0.0*−101%— | −0.0*—— | 2.0*—— | 3.0—— | 3.1*—— | |
| Cash from financing activities | 20+41.3%— | 1.8*−75.1%— | 1.4*−44.6%— | 0.4−83.1%— | 17*+616%— | 7.0*+770%— | 2.5*−75.4%— | 2.4—— | 2.3*−75.8%— | 0.8*—— | 10*—— | −0.1—— | 9.6*—— | |
| Exchange-rate effect on cash | −0.1—— | −0.1*−1510%— | −0.1*−154%— | 0.0−77.6%— | 0.1*—— | 0.0*−98.3%— | 0.3*+1882%— | 0.1—— | −0.5*−199%— | 0.4*—— | 0.0*—— | −0.4—— | 0.5*—— | |
| Change in cash | 2.9—— | −1.4*−166%— | −3.5*—— | −4.3—— | 12*—— | 2.1*—— | −2.4*−138%— | −1.3—— | −1.7*−122%— | −4.9*—— | 6.3*—— | −1.2—— | 7.5*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Gain Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 4 · Material agreement 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2020 | $10 M | No. 1 | $10 to $50 million | 48 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Gain Therapeutics, Inc. compares in Biotechnology
- Market cap$74 M · higher than 32% of 726
- Revenue growth-57.1% · higher than 16% of 438
- Price / book4.0× · lower than 38% of 534
- FCF yield-25.4% · higher than 38% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Gain Therapeutics, Inc.🇺🇸 | $74 M | — | — | -57.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 7, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Gain Therapeutics, Inc.? Verify and update this profile — free
Show Gain Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.